Treat Diabetic Foot Ulcers Pharmacologically
Chronic Wound Healing Using β3AR Agonists
Tags: The University of Sydney, Australia, Healthcare & Lifesciences
Stimulating β3 adrenoreceptors enhances blood flow and tissue healing. A topical lipogel effectively delivers Mirabegron, a β3AR agonist, promoting wound recovery. With a method-of-use patent, this approach targets conditions like diabetic foot ulcers, scleroderma, pressure sores, and peripheral arterial disease. The technology aims to fill a gap in diabetic ulcer treatments that include wound dressing or amputation. Current treatments lack pharmacological options to improve healing.
IP Type or Form Factor: Patent Pending; Process & Method; Material
TRL: 5 - prototype ready for testing in intended environment
Industry or Tech Area: Pharmaceutical Engineering; Healthcare Provider
